Premium
The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients
Author(s) -
Suzuki K.,
Kato K.,
Soda S.,
Kamimura T.,
Aizawa Y.
Publication year - 2004
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1462-8902.2004.00331.x
Subject(s) - valsartan , medicine , left ventricular hypertrophy , blood pressure , cardiology , angiotensin ii receptor antagonist , diabetes mellitus , type 2 diabetes , body mass index , type 2 diabetes mellitus , muscle hypertrophy , diastole , angiotensin ii , endocrinology , angiotensin receptor
Aim: The aim of the present study was to examine the effects of an angiotensin II receptor antagonist, valsartan, on echocardiographically proven left ventricular hypertrophy (LVH) in patients with type 2 diabetes. Methods: Outpatients with type 2 diabetes mellitus were recruited at Niigata University Hospital. The left ventricular mass index (LVMI) was calculated by echocardiography. LVH was considered to be present if the LVMI was > 131 g/m 2 in males and > 100 g/m 2 in females. Patients with LVH received a low dose (40 mg/day) of valsartan for 12 months. This low dose had no clinical effect on blood pressure. Results: Of the 38 patients who entered the study, 14 (36.8%) had LVH. After only 6 months of valsartan therapy, the mean LVMI decreased significantly, from 126.5 ± 27.8 to 119.0 ± 23.5 g/m 2 (p < 0.01 vs. baseline). Also, a significant decrease was observed after 12 months (116.5 ± 30.9 g/m 2 , p < 0.05 vs. baseline). Compared to baseline, there were no significant differences after treatment in body mass index, glycosylated haemoglobin (HbA 1c ), systolic blood pressure and diastolic blood pressure. Conclusions: In type 2 diabetic patients with LVH, treatment with a low dose of valsartan, an angiotensin II receptor antagonist, for 12 months, reduced LVMI, with no reduction in systemic blood pressure. This drug may be safely administered to type 2 diabetic patients with LVH. The long‐term risk‐reduction effects will have to be evaluated in further trials.